We are live on ! Find out more
SGMO

SANGAMO THERAPEUTICS INC

Delisted

SGMO was delisted on the 4th of May, 2026.

129 hedge funds and large institutions have $31.1M invested in SANGAMO THERAPEUTICS INC in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 28

2% less funds holding

Funds holding: 131129 (-2)

7.71% less ownership

Funds ownership: 49.58%41.88% (-7.7%)

25% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 44

52% less call options, than puts

Call options by funds: $29K | Put options by funds: $60K

54% less capital invested

Capital invested by funds: $68.2M → $31.1M (-$37.1M)

Holders
129
Holders Change
-2
Holders Change %
-1.53%
% of All Funds
1.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
26
Increased
33
Reduced
44
Closed
28
Calls
$29K
Puts
$60K
Net Calls
-$31K
Net Calls Change
+$44K

SGMO Hedge Fund Activity: Q2 2024 in Review

129 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q2 2024, worth a combined $31.1M — down 54% from $68.2M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of SGMO and 26 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 33 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $1.49M. The largest seller was BlackRock, cutting an estimated $4.63M.

  • 129 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q2 2024, down from 131 in Q1 2024.
  • Funds reported $31.1M of SANGAMO THERAPEUTICS INC stock for Q2 2024, down 54% quarter-over-quarter.
  • 26 funds opened new SANGAMO THERAPEUTICS INC positions in Q2 2024 and 28 closed out, a net change of -2 holders.
  • The largest SANGAMO THERAPEUTICS INC buyer in Q2 2024 was Jacobs Levy Equity Management, an estimated $1.49M added.
  • The largest SANGAMO THERAPEUTICS INC seller in Q2 2024 was BlackRock, an estimated $4.63M sold.

Based on aggregated 13F filings for Q2 2024.